Skip to main navigation Skip to search Skip to main content

A GLP-1/apelin dual receptor agonist shows neuroprotective effects in the MPTP mouse model of Parkinson's disease

  • Ao Xu
  • , Yinuo Wei
  • , Enhua Liu
  • , Wen Tong
  • , Ange Lu
  • , Feiyu Zhang
  • , Peter Flatt
  • , Victor Gault
  • , Nigel Irwin
  • , Christian Hölscher
  • , Zijuan Zhang
  • Zhengzhou University
  • Shanxi Medical University

Research output: Contribution to journal › Article › peer-review

47 Downloads (Pure)

Abstract

Parkinson's disease (PD) is a chronic disorder with no disease-modifying treatment available. The glucagon-like peptide-1 (GLP-1) class of drugs is on the market to treat diabetes and obesity. GLP-1 drugs have also shown neuroprotective effects in animal models and clinical trials in PD patients. Apelin (APJ) is an adipokine peptide hormone with neuroprotective actions in preclinical studies. Here, we test the effects of a rationally designed bifunctional peptide, namely ELA (exendin-4-linker-apelin), in the MPTP mouse model of PD. The single GLP-1 receptor agonist liraglutide was used as a comparator. Motor activity was improved by both drugs (open field, pole test, Rotarod), and the inflammation response was reduced (activation of microglia and astrocytes, pro-inflammatory cytokine levels). In addition, synapse numbers were improved in the striatum (Golgi strain, TEM), expression of synapse-associated proteins was enhanced, alongside reduced expression of genes that increase mitochondrial fission. Mitochondrial fusion gene expressions (Opa1, Mfn2, Drp1) and mitochondrial morphology were also normalized (TEM). ELA was superior to liraglutide in some, but not all, parameters measured. The results suggest that the rational design of bifunctional peptides targeting both GLP-1 and APJ pathways-with optimized pharmacokinetics and enhanced blood-brain barrier (BBB) permeability-merits further investigation as a strategy for developing more effective treatments for PD.

Original languageEnglish
Article number118534
Pages (from-to)1-14
Number of pages14
JournalBiochemical Pharmacology
Volume254
Issue numberPt 3
Early online date10 Oct 2026
DOIs
Publication statusPublished online - 10 Oct 2026

Bibliographical note

Copyright © 2026. Published by Elsevier Inc.

Rights Retention Statement

This Author Accepted Manuscript has been made open access under a Creative Commons Attribution 4.0 International licence (CC BY 4.0) under the terms of Ulster University Rights Retention Policy for Scholarly Works. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.

Data Availability Statement

Data will be available upon request.

Funding

Scientific and Technological Project of Henan Province (Grant No. 262102310553); Natural Science Foundation of Henan Province (Grant No. 262300421589); Special Scientific Research Project of Traditional Chinese Medicine in Henan Province (Grant No. 2024ZY3094).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Mitochondria
  • Synapse
  • inflammation
  • insulin
  • growth factors
  • brain
  • Brain
  • Inflammation
  • Growth factors
  • Insulin

Fingerprint

Dive into the research topics of 'A GLP-1/apelin dual receptor agonist shows neuroprotective effects in the MPTP mouse model of Parkinson's disease'. Together they form a unique fingerprint.

Cite this